BridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says

MT Newswires Live04-09

BridgeBio Pharma (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a Wednesday note.

RBC said Attruby is gaining early traction based on physician feedback and expects peak sales of around $3 billion. It added that while legal disputes over tafamidis remain an overhang, near-term generic risk to Vyndamax appears limited, and any longer-term impact should be manageable.

Beyond TTR, RBC sees BridgeBio's broader pipeline as a key value driver, projecting more than $2 billion in additional peak revenue from assets including infigratinib, encaleret, and BBP-418. The firm believes the portfolio is underappreciated and could help lift total revenue to around $5 billion with strong margins.

RBC also highlighted sustainability factors such as clinical trial practices, data transparency, and management diversity, noting the company is improving its governance and aligning with broader biotech industry standards.

RBC initiated coverage with an outperform rating with a price target of $100.

Shares of BridgeBio Pharma were down 0.9% in Thursday trading.

Price: 73.46, Change: -0.68, Percent Change: -0.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626136590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626136590","market":"us","top_or_hot":-1,"title":"BridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a Wednesday note.</p><p>RBC said Attruby is gaining early traction based on physician feedback and expects peak sales of around $3 billion. It added that while legal disputes over tafamidis remain an overhang, near-term generic risk to Vyndamax appears limited, and any longer-term impact should be manageable.</p><p>Beyond TTR, RBC sees BridgeBio's broader pipeline as a key value driver, projecting more than $2 billion in additional peak revenue from assets including infigratinib, encaleret, and BBP-418. The firm believes the portfolio is underappreciated and could help lift total revenue to around $5 billion with strong margins.</p><p>RBC also highlighted sustainability factors such as clinical trial practices, data transparency, and management diversity, noting the company is improving its governance and aligning with broader biotech industry standards.</p><p>RBC initiated coverage with an outperform rating with a price target of $100.</p><p>Shares of BridgeBio Pharma were down 0.9% in Thursday trading.</p><p>Price: 73.46, Change: -0.68, Percent Change: -0.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-09 23:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a Wednesday note.</p><p>RBC said Attruby is gaining early traction based on physician feedback and expects peak sales of around $3 billion. It added that while legal disputes over tafamidis remain an overhang, near-term generic risk to Vyndamax appears limited, and any longer-term impact should be manageable.</p><p>Beyond TTR, RBC sees BridgeBio's broader pipeline as a key value driver, projecting more than $2 billion in additional peak revenue from assets including infigratinib, encaleret, and BBP-418. The firm believes the portfolio is underappreciated and could help lift total revenue to around $5 billion with strong margins.</p><p>RBC also highlighted sustainability factors such as clinical trial practices, data transparency, and management diversity, noting the company is improving its governance and aligning with broader biotech industry standards.</p><p>RBC initiated coverage with an outperform rating with a price target of $100.</p><p>Shares of BridgeBio Pharma were down 0.9% in Thursday trading.</p><p>Price: 73.46, Change: -0.68, Percent Change: -0.92</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2626136590","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626136590","pubTimestamp":1775748325,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BridgeBio Pharma  is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a Wednesday note.RBC said Attruby is gaining early traction based on physician feedback and expects peak sales of around $3 billion. It added that while legal disputes over tafamidis remain an overhang, near-term generic risk to Vyndamax appears limited, and any longer-term impact should be manageable.Beyond TTR, RBC sees BridgeBio's broader pipeline as a key value driver, projecting more than $2 billion in additional peak revenue from assets including infigratinib, encaleret, and BBP-418. The firm believes the portfolio is underappreciated and could help lift total revenue to around $5 billion with strong margins.RBC also highlighted sustainability factors such as clinical trial practices, data transparency, and management diversity, noting the company is improving its governance and aligning","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BBIO":"BridgeBio Pharma, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓"},"translate_title":"RBC表示，BridgeBio Pharma正在从TTR发展成为罕见病巨头","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1},"content_text":"BridgeBio Pharma (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a Wednesday note.RBC said Attruby is gaining early traction based on physician feedback and expects peak sales of around $3 billion. It added that while legal disputes over tafamidis remain an overhang, near-term generic risk to Vyndamax appears limited, and any longer-term impact should be manageable.Beyond TTR, RBC sees BridgeBio's broader pipeline as a key value driver, projecting more than $2 billion in additional peak revenue from assets including infigratinib, encaleret, and BBP-418. The firm believes the portfolio is underappreciated and could help lift total revenue to around $5 billion with strong margins.RBC also highlighted sustainability factors such as clinical trial practices, data transparency, and management diversity, noting the company is improving its governance and aligning with broader biotech industry standards.RBC initiated coverage with an outperform rating with a price target of $100.Shares of BridgeBio Pharma were down 0.9% in Thursday trading.Price: 73.46, Change: -0.68, Percent Change: -0.92","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626136590","isCrawlerRequest":true}